|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 35.10 HKD | +2.15% |
|
-8.36% | -29.66% |
| Dec. 03 | Jefferies Adjusts Giant Biogene's Price Target to HK$55 From HK$72, Keeps at Buy | MT |
| Dec. 02 | Giant Biogene Plans Share Buyback | MT |
| Capitalization | 34.07B 37.59B 4.83B 4.11B 3.84B 3.62B 6.66B 437B 7.27B 44.85B 17.4B 206B 18.12B 17.74B 752B | P/E ratio 2025 * |
15x | P/E ratio 2026 * | 12.2x |
|---|---|---|---|---|---|
| Enterprise value | 27.92B 30.81B 3.96B 3.37B 3.15B 2.96B 5.46B 358B 5.96B 36.76B 14.26B 169B 14.85B 14.54B 616B | EV / Sales 2025 * |
4.45x | EV / Sales 2026 * | 3.41x |
| Free-Float |
42.68% | Yield 2025 * |
3.67% | Yield 2026 * | 4.31% |
| 1 day | +2.15% | ||
| 1 week | -8.36% | ||
| Current month | -2.99% | ||
| 1 month | -10.82% | ||
| 3 months | -44.15% | ||
| 6 months | -40.96% | ||
| Current year | -29.66% |
| 1 week | 34.18 |  | 36.72 |
| 1 month | 34.18 | | 41.32 |
| Current year | 34.18 | | 87.1 |
| 1 year | 34.18 | | 87.1 |
| 3 years | 28.4 | | 87.1 |
| 5 years | 24.3 | | 87.1 |
| 10 years | 24.3 | | 87.1 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jian Ya Yan
CEO | Chief Executive Officer | 58 | 2022-04-20 |
Hui Juan Zhang
DFI | Director of Finance/CFO | 38 | 2022-04-20 |
Yu Bo Yan
SEC | Corporate Secretary | 29 | 2018-09-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Jian Ya Yan
CHM | Chairman | 58 | 2022-04-20 |
Juan Ye
BRD | Director/Board Member | 54 | 2021-11-29 |
Jin Huang
BRD | Director/Board Member | 66 | 2022-10-05 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.15% | -8.36% | -32.04% | +10.90% | 4.83B | |
| +1.48% | -0.43% | -16.50% | -6.54% | 334B | |
| -0.37% | -3.54% | -7.82% | +3.56% | 143B | |
| +1.41% | +0.35% | -16.16% | -1.26% | 63.15B | |
| -1.95% | -3.34% | -5.42% | -16.59% | 58.64B | |
| -1.38% | -0.98% | +30.06% | -58.23% | 37.51B | |
| +0.06% | +2.36% | -21.97% | - | 33.2B | |
| -0.91% | +2.93% | -25.07% | -12.35% | 23.98B | |
| +1.35% | +0.42% | -11.94% | -5.47% | 19.31B | |
| +0.51% | +1.57% | +3.81% | +31.59% | 13.03B | |
| Average | +0.23% | -0.93% | -10.31% | -6.04% | 73.04B | |
| Weighted average by Cap. | +0.53% | -1.00% | -11.64% | -6.96% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 6.28B 6.93B 890M 758M 708M 666M 1.23B 80.6B 1.34B 8.27B 3.21B 37.99B 3.34B 3.27B 139B | 7.81B 8.62B 1.11B 943M 881M 829M 1.53B 100B 1.67B 10.28B 3.99B 47.27B 4.15B 4.07B 172B |
| Net income | 2.26B 2.49B 320M 273M 255M 240M 441M 29.01B 482M 2.97B 1.15B 13.67B 1.2B 1.18B 49.88B | 2.79B 3.08B 396M 337M 315M 296M 546M 35.85B 596M 3.68B 1.43B 16.9B 1.49B 1.45B 61.65B |
| Net Debt | -6.15B -6.78B -871M -742M -693M -652M -1.2B -78.9B -1.31B -8.09B -3.14B -37.19B -3.27B -3.2B -136B | -7.45B -8.21B -1.06B -899M -840M -790M -1.45B -95.58B -1.59B -9.8B -3.8B -45.05B -3.96B -3.88B -164B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-12-12 | 35.10 $ | +2.15% | 7,149,092 |
| 25-12-11 | 34.36 $ | -5.08% | 16,197,470 |
| 25-12-10 | 36.20 $ | +0.06% | 5,356,062 |
| 25-12-09 | 36.18 $ | -0.60% | 6,585,926 |
| 25-12-08 | 36.40 $ | -4.96% | 13,477,700 |
Delayed Quote Hong Kong S.E., December 12, 2025 at 03:08 am EST
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 2367 Stock
Select your edition
All financial news and data tailored to specific country editions
